{ "meta": { "data_length": 1, "message": "Statement id stmt:hse:00328:a:0 retrieved successfully", "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Ahse%3A00328%3Aa%3A0", "status": "success", "status_code": 200, "timestamp_elapsed": 0.00213, "timestamp_received": "2026-10-16T23:59:24.220063+00:00Z", "timestamp_returned": "2026-10-16T23:59:24.222193+00:00Z", "trace_id": "7b910742-29c8-441f-b105-aeaa73992ad8" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:hse:00328:a:0", "type": "Statement", "description": "The Republic of Ireland's Health Service Executive (HSE) has approved cetuximab (7 days) in combination with FOLFIRI (14 days) for reimbursement as a treatment option for the treatment of adult patients with RAS wild type metastatic colorectal cancer. The European Medicine Agency's product information for Erbitux (cetuximab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.", "contributions": [ { "id": "ctrb:vanallenlab:2024-01-16:0", "type": "Contribution", "description": "Adding HSE approvals for reimbursement to database", "date": "2024-01-16", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:hse:2016-06-03:0", "type": "Contribution", "description": "Indication approved for reimbursement.", "date": "2016-06-03", "contributor": { "id": "agent:org:hse", "type": "Agent", "agentType": "organization", "name": "Health Service Executive", "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland." } } ], "reportedIn": [ { "id": "doc:hse:00328", "type": "Document", "documentType": "Regulatory approval", "name": "Cetuximab (7 days) and FOLFIRI (14 days) Therapy. NCCP National SACT Regimen. HSE.", "title": null, "aliases": [], "description": "Cetuximab (7 days) and FOLFIRI (14 days) Therapy, 2026, version number 7, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6773/328_v6b_Cetuximab_7_days_FOLFIRI_14_Days.pdf", "urls": [ "https://healthservice.hse.ie/documents/6773/328_v6b_Cetuximab_7_days_FOLFIRI_14_Days.pdf" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:hse", "type": "Agent", "agentType": "organization", "name": "Health Service Executive", "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland." }, "description": "The organization that published this document." }, { "name": "company", "value": "", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": null, "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": null, "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2026-06-23", "description": "The publication date for the document." }, { "name": "status", "value": "Deprecated", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:797", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:ncit:C5105", "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2025_10_03", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Colorectal+Adenocarcinoma+%28COADREAD%29" ] } } ], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:ncit:C5105", "code": "C5105", "name": "Colorectal Adenocarcinoma", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C5105" ] } }, "objectTherapeutic": { "id": "txgrp:14", "membershipOperator": "AND", "therapies": [ { "id": "tx:ncit:C1723", "conceptType": "Therapy", "name": "Cetuximab", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:318341", "code": "318341", "name": "cetuximab", "system": "RxNorm", "systemVersion": "20250602", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=318341" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1315411", "code": "1315411", "name": "cetuximab", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1315411" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "EGFR inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C1723", "code": "C1723", "name": "Cetuximab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1723" ] } }, { "id": "tx:ncit:C62040", "conceptType": "Therapy", "name": "Irinotecan", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:51499", "code": "51499", "name": "irinotecan", "system": "RxNorm", "systemVersion": "20250602", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=51499" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1367268", "code": "1367268", "name": "irinotecan", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1367268" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "Topoisomerase I inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C62040", "code": "C62040", "name": "Irinotecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62040" ] } }, { "id": "tx:ncit:C505", "conceptType": "Therapy", "name": "Fluorouracil", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:4492", "code": "4492", "name": "fluorouracil", "system": "RxNorm", "systemVersion": "20250602", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=4492" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:955632", "code": "955632", "name": "fluorouracil", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/955632" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "Thymidylate synthase inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505" ] } } ] }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:25", "present": true, "subject": { "id": "bmkr:25", "type": "CategoricalVariant", "name": "Wild type KRAS", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.fHPHbS6fyaj8MlrRusLFIqH1yXxUPvso", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Sequence spanning the length of refseq:NP_004976.2, the protein product of the MANE Select coding transcript for KRAS (refseq:NM_004985.5).", "digest": "fHPHbS6fyaj8MlrRusLFIqH1yXxUPvso", "sequenceReference": { "id": "ga4gh:SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS", "type": "SequenceReference", "name": "NP_004976.2", "aliases": [ "ensembl:ENSP00000308495.3", "ga4gh:SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS", "refseq:NP_004976.2" ], "description": "The protein product of the MANE Select coding transcript for KRAS (refseq:NM_004985.5), corresponding to the Refseq protein accession NP_004976.2.", "moleculeType": "protein", "refgetAccession": "SQ.fytWhQSNGnA-86vDiQCxTSzgkk_WfQRS", "residueAlphabet": "aa" }, "start": 0, "end": 188, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:6407", "conceptType": "Gene", "name": "KRAS", "primaryCoding": { "id": "coding:hgnc:6407", "code": "HGNC:6407", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000133703", "code": "ENSG00000133703", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000133703" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:3845", "code": "3845", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/3845" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_004985.5", "code": "NM_004985.5", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Wild type" } ] } }, { "id": "bmkr.criterion:27", "present": true, "subject": { "id": "bmkr:27", "type": "CategoricalVariant", "name": "Wild type NRAS", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.PIDoTr_OYRkt1CZjDo1wtFyVCxYx-VHd", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Sequence spanning the length of refseq:NP_002515.1, the protein product of the MANE Select coding transcript for NRAS (refseq:NM_002524.5).", "digest": "PIDoTr_OYRkt1CZjDo1wtFyVCxYx-VHd", "sequenceReference": { "id": "ga4gh:SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18", "type": "SequenceReference", "name": "NP_002515.1", "aliases": [ "ensembl:ENSP00000358548.4", "ga4gh:SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18", "refseq:NP_002515.1" ], "description": "The protein product of the MANE Select coding transcript for NRAS (refseq:NM_002524.5), corresponding to the Refseq protein accession NP_002515.1.", "moleculeType": "protein", "refgetAccession": "SQ.974-EgvIQKi6ptqsI6XUZthCv-Py3S18", "residueAlphabet": "aa" }, "start": 0, "end": 189, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:7989", "conceptType": "Gene", "name": "NRAS", "primaryCoding": { "id": "coding:hgnc:7989", "code": "HGNC:7989", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7989" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000213281", "code": "ENSG00000213281", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000213281" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:4893", "code": "4893", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/4893" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_002524.5", "code": "NM_002524.5", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_002524.5" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Wild type" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Deprecated", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:hse:00328:a", "type": "Indication", "description": "Treatment of patients with RAS wild type metastatic colorectal cancer.", "contributions": [ { "id": "ctrb:vanallenlab:2024-01-16:0", "type": "Contribution", "description": "Adding HSE approvals for reimbursement to database", "date": "2024-01-16", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:hse:2016-06-03:0", "type": "Contribution", "description": "Indication approved for reimbursement.", "date": "2016-06-03", "contributor": { "id": "agent:org:hse", "type": "Agent", "agentType": "organization", "name": "Health Service Executive", "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland." } } ], "reportedIn": [ { "id": "doc:hse:00328", "type": "Document", "documentType": "Regulatory approval", "name": "Cetuximab (7 days) and FOLFIRI (14 days) Therapy. NCCP National SACT Regimen. HSE.", "title": null, "aliases": [], "description": "Cetuximab (7 days) and FOLFIRI (14 days) Therapy, 2026, version number 7, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6773/328_v6b_Cetuximab_7_days_FOLFIRI_14_Days.pdf", "urls": [ "https://healthservice.hse.ie/documents/6773/328_v6b_Cetuximab_7_days_FOLFIRI_14_Days.pdf" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:hse", "type": "Agent", "agentType": "organization", "name": "Health Service Executive", "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland." }, "description": "The organization that published this document." }, { "name": "company", "value": "", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": null, "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": null, "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2026-06-23", "description": "The publication date for the document." }, { "name": "status", "value": "Deprecated", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Withdrawn", "description": "Current approval status." }, { "name": "reimbursement_scheme", "value": "N/A", "description": "Current scheme used to reimburse indication." }, { "name": "reimbursement_comment", "value": null, "description": "More details about the current reimbursement scheme(s)." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }